Compare DexCom, Inc. (DXCM) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Phillips 66 — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Phillips 66 trades at $278.18 (market cap $112.36B). The key difference: Phillips 66 is far larger — about 3.5× DexCom, Inc.'s market cap, and Phillips 66 pays a 1.8% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Phillips 66 for 62 Days on average.
| DXCM | PSX | |
|---|---|---|
Market Cap | $31.86B | $112.36B |
Volume | 3,607,070 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $92.34 | $281.60 |
52-Week Low | $54.84 | $126.76 |
Typical Hold Time | 62 Days | 62 Days |
Enterprise Value | $31.32B | $128.83B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
Phillips 66 (PSX) trades at $281.60, up 3.67% with strong technical momentum as it approaches resistance at $284. The stock shows robust fundamentals with three consecutive earnings beats and improving cash flow projections for 2026. Recent news highlights structural refining advantages and AI implementation for operational efficiency, supporting the bullish analyst consensus.
PSX offers attractive valuation with P/E of 16.07 and P/S of 0.75, coupled with strong profitability metrics including 24.02% ROE. Key risks include commodity price volatility and potential policy impacts on diesel exports. With 54% analyst buy ratings and $279 consensus target, the stock presents growth potential despite near-term overbought technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
